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Abstract. 
 
The Ras target AF-6 has been shown to 
serve as one of the peripheral components of cell–cell 
adhesions, and is thought to participate in cell–cell ad-
hesion regulation downstream of Ras. We here purified 
an AF-6-interacting protein with a molecular mass of 
 
z
 
220 kD (p220) to investigate the function of AF-6 at 
cell–cell adhesions. The peptide sequences of p220 
were identical to the amino acid sequences of mouse 
Fam. Fam is homologous to a deubiquitinating enzyme 
 
in 
 
Drosophila
 
, the product of the 
 
fat facets
 
 gene. Recent 
genetic analyses indicate that the deubiquitinating ac-
tivity of the 
 
fat
 
 
 
facets
 
 product plays a critical role in con-
trolling the cell fate. We found that Fam accumulated 
at the cell–cell contact sites of MDCKII cells, but not at 
free ends of plasma membranes. Fam was partially 
colocalized with AF-6 and interacted with AF-6 in vivo 
and in vitro. We also showed that AF-6 was ubiquiti-
nated in intact cells, and that Fam prevented the ubiq-
uitination of AF-6. 
These results indicate that AF-6 forms a complex
with and serves as one of the substrates for Fam, and
suggest that the degradation of peripheral components
of cell–cell adhesions may be regulated by Fam. 
Key words: AF-6 • Fam • deubiquitinating enzyme • 
ubiquitination • cell–cell adhesions
 
R
 
as
 
 (Ha-Ras, Ki-Ras, N-Ras) is a signal-transducing
guanine nucleotide-binding protein for tyrosine ki-
nase–type receptors such as epidermal growth fac-
tor receptors and the Src family (for reviews see Satoh
et al., 1992; McCormick, 1994). Ras has GDP-bound inac-
tive and GTP-bound active forms, the latter of which
make physical contact with targets (Marshall, 1995
 
a
 
). In-
tensive investigations revealed that the Raf kinase family,
consisting of c-Raf-1 (for reviews see Blenis, 1993; Daum
et al., 1994), A-Raf (Vojtek et al., 1993), and B-Raf
(Moodie et al., 1994; Jaiswal et al., 1994; Catling et al.,
1994; Yamamori et al., 1995), is one of the direct targets
for Ras. The activated Raf phosphorylates mitogen-acti-
 
vated protein (MAP)
 
1
 
 kinase kinase and activates it. Con-
sequently, the activated MAP kinase kinase activates
MAP kinase, leading to the expression of certain genes
such as c-
 
fos
 
 (for reviews see Cano and Mahadevan, 1995;
Marshall, 1995
 
b
 
). Several molecules interacting with acti-
vated Ras in addition to Raf have been identified in mam-
mals. These include phosphatidylinositol-3-OH kinase
(Rodriguez-Viciana et al., 1994), Ral guanine nucleotide
dissociation stimulator (Kikuchi et al., 1994; Spaargaren
and Bischoff, 1994), and Rin1 (Han and Colicelli, 1995).
We previously identified the acute lymphoblastic leuke-
mia-1 (ALL-1) fusion partner from chromosome 6 (AF-6)
as a Ras target (Kuriyama et al., 1996). AF-6 was identi-
fied as the fusion partner of ALL-1 protein (Prasad et al.,
1993). The ALL-1/AF-6 chimeric protein is a critical prod-
uct of the t(6;11) abnormality associated with some human
leukemia. AF-6 has the postsynaptic density protein PSD-
95/discs-large tumor suppressor protein Dlg/ZO-1 (PDZ)
domain, which is thought to localize AF-6 at the special-
ized sites of plasma membranes such as cell–cell contact
sites.
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1. 
 
Abbreviations used in this paper
 
: ALL-1, acute lymphoblastic
leukemia-1; ALLM, 
 
N
 
-acetyl-Leu-Leu-methional; ALLN, 
 
N
 
-acetyl-Leu-
Leu-norleucinal; HA-Ub, hemagglutinin-tagged ubiquitin; GST, glu-
 
tathione-
 
S
 
-transferase; MAP, mitogen-activated protein; MBP, maltose-
binding protein; 
 
p
 
-APMSF, (
 
p
 
-amidino-phenyl)methanesulfonyl fluoride;
SH3, src homology region 3; Ub, ubiquitin; Ubps, ubiquitin-specific pro-
teases; Ub-PEST, ubiquitin-
 
a
 
NH-MHISPPEPESEEEEEHYC; ZO-1,
zonula occludens-1.
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We have recently found that AF-6 accumulates at tight
junctions in epithelial cells such as MDCKII cells and at
cell–cell adhesions in nonepithelial cells such as Rat1 fi-
broblasts and PC12 rat pheochromocytoma cells (Yama-
moto et al., 1997). AF-6 interacts with ZO-1 in vitro. ZO-1
interacts with the Ras-binding domain of AF-6, and this
interaction is inhibited by activated Ras. Overexpression
of activated Ras in Rat1 cells results in perturbation of
cell–cell contacts, followed by a decrease of the accumula-
tion of AF-6 and ZO-1 at the cell surface (Yamamoto
 
 
 
et al.,
1997). These observations indicate that AF-6 serves as one
of the peripheral components of tight junctions in epithe-
lial cells and of cell–cell adhesions in nonepithelial cells,
and that AF-6 may participate in the regulation of cell–cell
contacts including tight junctions via direct interaction
with ZO-1 downstream of Ras. To understand the func-
tion of AF-6 at cell–cell contact sites, we here attempted to
identify AF-6–interacting molecules. We purified an AF-
6–interacting protein with a molecular mass of 
 
z
 
220 kD,
and identified it as the bovine counterpart of mouse Fam
protein (Wood et al., 1997).
Fam is homologous to a deubiquitinating enzyme in
 
Drosophila
 
, the product of the 
 
fat facets 
 
(
 
faf
 
) gene (Fi-
scher-Vize et al., 1992; Huang et al., 1995; Huang and Fi-
scher-Vize, 1996). The 
 
faf
 
 gene is specifically required for
normal eye development in 
 
Drosophila
 
. The ubiquitin-
proteasome pathway plays an important role in the com-
plete degradation of abnormal and short-lived regulatory
proteins that include transcriptional activators such as c-fos,
NF
 
k
 
B-I
 
k
 
B complex, and p53, or growth factor receptors
such as platelet-derived growth factor receptor (PDGFR)
and fibroblast growth factor 1 receptor (FGFR-1; Hoch-
strasser, 1995; Hicke, 1997). This pathway requires ATP
and a covalent conjugation of the ubiquitin (Ub) mole-
cules. The conjugation involves a series of enzymatic reac-
tions: Ub itself is first activated with ATP by the Ub-acti-
vating enzyme (E1), secondly transferred onto a Ub
carrier protein (E2), and in a third step transferred onto a
Ub ligase (E3). Multiubiquitinated substrates are then rec-
ognized by the 26S proteasome and rapidly degraded into
short peptides.
A large superfamily of genes encoding deubiquitinating
enzymes, ubiquitin-specific proteases (Ubps), was recently
identified (Hochstrasser, 1995). The deubiquitinating en-
zymes can generally be divided into two main types. The
first one is thought to remove ubiquitin from Ub-conju-
gated degradation products produced by the proteasomes,
and thereby to accelerate the proteasome-dependent pro-
teolysis. This type is present in all cells, and is thought to
have little substrate specificity. The second one is thought
to remove Ub from multiubiquitinated substrates, and
thereby to prevent their proteasome-dependent proteoly-
sis before they reach the proteasome. This type shows a
tissue-specific expression pattern, and is thought to have
substrate specificity (Hochstrasser, 1995). Recent genetic
analyses indicate that Faf belongs to the second type, and
that the deubiquitinating activity of Faf is essential for reg-
ulating a cell communication pathway essential for normal
eye development (Huang
 
 
 
et al., 1995; Huang and Fischer-
Vize, 1996). In situ hybridization analyses revealed that
mouse Fam transcripts exist in the rapidly expanding cell
population of gastrulating and neurulating embryos, and
in postmitotic cells of the central nervous system as well as
in the apoptotic regions between digits (Wood et al.,
1997), although the role and the physiological substrate of
mammalian Fam are unknown.
In this study, we found that Fam accumulated at cell–
cell contacts, and that AF-6 interacted with Fam both in
vivo and in vitro. We also found that AF-6 was ubiquiti-
nated in intact cells and that Fam prevented the ubiquiti-
nation of AF-6.
 
Materials and Methods
 
Materials and Chemicals
 
The Fam cDNA clone was generated as described previously (Wood
 
 
 
et al.,
1997). MDCKII cells, EL cells, and the mouse antibody against ZO-1
were kindly provided by Drs. A. Nagafuchi and S. Tsukita (University of
Kyoto, Kyoto, Japan) (Itoh et al., 1991; Nagafuchi et al., 1994). pMT123
(HA-ubiquitin expression plasmid) was kindly provided by Dr. D. Boh-
mann (European Molecular Biology Laboratory, Heidelberg, Germany)
(Treier et al., 1994). Rabbit polyclonal antibodies against AF-6 (914–1129
aa; #3), AF-6 (1130–1612 aa; #4), Fam (1–20 aa; N20), Fam (2441–2554 aa;
C114), and Fam (1165–1967 aa; K2) were generated as described previ-
ously (Harlow and Lame, 1988). FITC-conjugated anti-rabbit IgG anti-
body, Texas red–conjugated anti-mouse IgG antibody, and [
 
35
 
S]methio-
nine were purchased from Amersham Corp. (Buckinghamshire, United
Kingdom). Mouse monoclonal antibody against 
 
b
 
-catenin was purchased
from Transduction Laboratories (Lexington, KY). Rabbit polyclonal anti-
bodies against 
 
a
 
-catenin and 
 
b
 
-catenin were purchased from Sigma
Chemical Co. (St. Louis, MO). Polyvinylidene difluoride membranes
(Problott, 0.45-
 
m
 
m pore size) were purchased from PE Applied Biosys-
tems (Foster, CA). 
 
Achromobacter
 
 protease I was purchased from Wako
Pure Chemical Industries, Ltd. (Osaka, Japan). Proteasome inhibitor
ALLN (
 
N
 
-acetyl-Leu-Leu-norleucinal) and calpain inhibitor II ALLM
(
 
N
 
-acetyl-Leu-Leu-methional) were purchased from Peptide Institute,
Inc. (Osaka, Japan). All materials used in the nucleic acid study were pur-
chased from Takara Shuzo Corp. (Kyoto, Japan). Other materials and
chemicals were obtained from commercial sources.
 
Plasmid Construction
 
The 
 
Escherichia coli
 
 expression plasmid pGEX-3X-AF-6 (1130–1612 aa)
was constructed by subcloning the PvuII and EcoRI fragments of AF-6
into the SmaI and EcoRI sites of pGEX-3X. The plasmids for in vitro
translation of Fam were constructed by amplifying the cDNA fragments
encoding Fam (1–669 aa, 670–1213 aa, 1210–2100 aa, and 2097–2554 aa)
by PCR from the full-length Fam cDNA in pBluescript SK(
 
2
 
). The frag-
ment of Fam (1–669 aa) was amplified using the sense primer containing
a BamHI site (5
 
9
 
-AATTGGATCCATGACAGCCACGACTCGTG-3
 
9
 
)
and the antisense primer containing a BamHI site (5
 
9
 
-ATTAGGATCCT-
CACAGCTGGCCATCCTTCA-3
 
9
 
). The fragment of Fam (670–1213 aa)
was amplified using the sense primer containing a BamHI site (5
 
9
 
-AAT-
TGGATCCCTGTGGCTGTGTGCTCCAC-3
 
9
 
) and the antisense primer
containing a BamHI site (5
 
9
 
-ATTAGGATCCTCAGCATGCATTCA-
GATGATGGG-3
 
9
 
). The fragment of Fam (1210–2100 aa) was amplified
using the sense primer containing a BamHI site (5
 
9
 
-AATTGGATCCTG-
CATGCTTAGAAACGTGTC-3
 
9
 
) and the antisense primer containing
a BamHI site (5
 
9
 
-ATTAGGATCCTTACTCAGAGAATCGATTTG-
AAAC-3
 
9
 
). The fragment of Fam (2097–2554 aa) was amplified using the
sense primer containing a BamHI site (5
 
9
 
-AATTGGATCCCGATT-
CTCTGAGTACCTTTTG-3
 
9
 
) and the antisense primer containing a
BamHI site (5
 
9
 
-ATTAGGATCCTTAATATGTGCATTTCACTGATC-
3
 
9
 
). The fragments (1–669 aa, 670–1213 aa, and 2097–2554 aa) were cloned
into the BamHI site of pRSET-A, and the fragment (1210–2100 aa) was
cloned into the BamHI site of pBluescript SK(
 
2
 
). The 
 
Escherichia coli
 
 ex-
pression plasmid pMal-c2-Fam (1476–1918 aa) was constructed by inserting
the blunt-ended PstI and BstXI fragment of Fam into pMal-c2. The mam-
malian expression plasmid pEF-BOS-AF-6-myc was constructed as follows:
the cDNA fragments encoding AF-6 were subcloned into pBluescript SK(
 
2
 
)
having a sequence encoding a myc epitope tag (MEQKLISEEDL), and
AF-6-myc cDNA fragment was inserted into the XbaI site of pEF-BOS.
For the preparation of pEF-BOS-HA-Fam-CAT (1210–2410 aa), the frag- 
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ment (1210–2410 aa) was subcloned into pBluescript SK(
 
2
 
), and the frag-
ment was inserted into the BamHI site of pEF-BOS-HA.
 
Cell Culture
 
MDCKII and Rat1 cells were grown in DME containing 10% calf serum,
penicillin, and streptomycin in an air-5% CO
 
2
 
 atmosphere at constant hu-
midity. EL cells were grown in DME containing 10% FBS and 100 
 
m
 
g/ml
of G418 in an air-5% CO
 
2
 
 atmosphere at constant humidity. COS7 cells
were grown in DME containing 10% FBS, penicillin, and streptomycin in
an air-5% CO
 
2
 
 atmosphere at constant humidity.
 
Preparation of Bovine Brain Cytosolic Fraction
 
100 g of bovine brain gray matter was cut into small pieces with scissors
and suspended in 300 ml of homogenizing buffer A (25 mM Tris/HCl at
pH 7.5, 1 mM EDTA, 1 mM DTT, 10 mM MgCl
 
2
 
, 10 
 
m
 
M [
 
p
 
-amidino-phe-
nyl]methanesulfonyl fluoride [
 
p
 
-APMSF], 1 
 
m
 
g/ml leupeptin, 10% sucrose).
The suspension was homogenized with a Potter-Elvehjem Tefron-glass
homogenizer and filtered through four layers of gauze. The homogenate
was centrifuged at 20,000 
 
g
 
 for 30 min at 4
 
8
 
C and then at 100,000 
 
g
 
 for 60
min at 4
 
8
 
C as described (Yamamoto et al., 1995). The supernatant was
stored at 
 
2
 
80
 
8
 
C as the cytosolic fraction.
 
GST-AF-6 (1130–1612 aa) Affinity
Column Chromatography
 
Glutathione-
 
S
 
-transferase (GST)-AF-6 (1130–1612 aa) was expressed in
 
Escherichia coli
 
 BL21 (DE3) and purified according to the manufacturer’s
instructions. Glutathione-Sepharose 4B (1 ml) was coated with GST-AF-6
(1130–1612 aa; 30 nmol). The brain cytosolic fraction was then preab-
sorbed to remove the native GST with glutathione-Sepharose 4B and
loaded onto the GST-AF-6 (1130–1612 aa) affinity column. The column
was washed with 10 ml of buffer B (20 mM Tris/HCl at pH 7.5, 1 mM
EDTA, 1 mM DTT, 5 mM MgCl
 
2
 
, 10 
 
m
 
M 
 
p
 
-APMSF, 1 
 
m
 
g/ml leupeptin)
followed by washing with 10 ml of buffer B containing 75 mM NaCl. The
protein bound to the affinity column was eluted 10 times with 1 ml of
buffer B containing 10 mM reduced glutathione.
 
Peptide Sequence Analysis of p220
 
The 10-mM reduced glutathione eluates from the first to seventh fractions
were dialyzed three times against distilled water and concentrated by
freeze-drying. The concentrated samples were subjected to SDS-PAGE
and transferred onto polyvinylidene difluoride membranes (Iwamatsu,
1992). The immobilized p220 was reduced and 
 
S
 
-carboxymethylated, fol-
lowed by in situ digestion with 
 
Achromobacter
 
 protease
 
 
 
I and Asp-N. The
digested peptides were fractionated by C18 column chromatography and
subjected to amino acid sequencing (Iwamatsu, 1992).
 
Hydrolysis Assay of Ub-PEST
 
For purification of Fam, the brain cytosolic fraction was loaded onto the
GST-AF-6 (1130–1612 aa) affinity column. Fam was eluted by adding
buffer B containing 200 mM NaCl from the GST-AF-6 affinity column.
Ubiquitin-
 
a
 
NH-MHISPPEPESEEEEEHYC (Ub-PEST) was radiola-
beled with Na
 
125
 
I using IODO-BEADS (Markwell, 1982). Fam (1.6 
 
m
 
g)
was incubated for various periods at 37
 
8
 
C in a final volume (50 
 
m
 
l) con-
taining 1 
 
m
 
g of 
 
125
 
I-labeled Ub-PEST, 100 mM Tris/HCl at pH 7.5, 1 mM
EDTA, 1 mM DTT, and 5% (vol/vol) glycerol. The reaction was termi-
nated by adding 50 
 
m
 
l of acetone, and the mixture was frozen overnight at
 
2
 
80
 
8
 
C. The pellet fractions were boiled in sample buffer for SDS-PAGE,
and were subjected to SDS-PAGE detected by Coomassie Brilliant Blue
staining and by autoradiography (Woo et al., 1995).
 
Immunofluorescence and Laser Scanning
Confocal Microscopy
 
MDCKII cells plated on 13-mm round glass coverslips were fixed with
methanol for 10 min. The fixed cells were incubated for 2 h with mouse
monoclonal antibodies against ZO-1 or 
 
b
 
-catenin, and were washed three
times for 10 min with PBS. The cells were then incubated for 2 h with anti-
Fam antibody (K2) and washed three times for 10 min with PBS. The cells
were incubated for 1 h with FITC-conjugated anti-rabbit IgG antibody
and Texas red–conjugated anti-mouse IgG antibody, and washed three
times for 10 min with PBS. The distributions of Fam, ZO-1, and 
 
b
 
-catenin
were examined using a laser scanning confocal microscope (Carl Zeiss,
Inc., Thornwood, NY) equipped with an argon laser and a helium-neon la-
ser for double fluorescence at 488 and 543 nm (emission filter; BP510–525
and LP590).
 
Coimmunoprecipitation Assay
 
MDCKII cells were grown in 100-mm tissue culture dishes. After being
washed with PBS, the cells were lysed with 1 ml of buffer C (50 mM Tris/
HCl at pH 8.0, 1 mM EDTA, 75 mM NaCl, 1 mM MgCl
 
2
 
, 0.2% Triton
X-100, 10 
 
m
 
M 
 
p
 
-APMSF, 10 
 
m
 
g/ml leupeptin). The lysate was removed
from the dishes with a rubber policeman. The lysate was sonicated, incu-
bated in a 1.5-ml tube for 15 min on ice, and then clarified by centrifuga-
tion at 12,000 
 
g
 
 for 30 min at 4
 
8
 
C. The soluble supernatant was incubated
with 10 
 
m
 
g of anti-Fam antibody (K2), anti-AF-6 antibody (#3), or preim-
muneserum. The immunocomplexes were then precipitated with protein
A-Sepharose 4B (Pharmacia LKB Biotechnology AB, Uppsala, Sweden).
The immunocomplexes were washed six times with buffer C, eluted by
boiling in sample buffer for SDS-PAGE and subjected to immunoblot
analysis using anti-Fam antibody (N20) or anti-AF-6 antibody (#4).
 
In Vitro Binding Assay (In Vitro–translated Fam)
 
In vitro translation of pRSET-Fam (1–669 aa), pRSET-Fam (670–1213
aa), pBluescript SK(
 
2
 
)-Fam (1210–2100 aa), and pRSET-Fam (2097–
2554 aa) were performed using a TNT T7-coupled reticulocyte lysate sys-
tem (Promega Corp., Madison, WI) under the conditions described in the
manufacturer’s instruction manual. Glutathione-Sepharose 4B beads (31 
 
m
 
l)
were coated with GST fusion proteins and washed with 310 
 
m
 
l of buffer B.
The coated beads were added to 40 
 
m
 
l of the in vitro–translated products
labeled with [
 
35
 
S]methionine containing 1 mg/ml BSA, and were incu-
bated for 1 h at 48C with gentle mixing. The beads were washed six times
with 102 ml of buffer B, and the bound proteins were coeluted with GST
fusion proteins three times by adding 102 ml of buffer B containing 10 mM
reduced glutathione. The eluates were subjected to SDS-PAGE and vac-
uum-dried. The [35S]-labeled bands corresponding to in vitro–translated
Fam were visualized with an image analyzer (BAS-2000; Fuji Photo Film
Co., Tokyo, Japan).
In Vitro Binding Assay (Maltose-binding
Protein [MBP]–Fam)
The deubiquitinating catalytic domain of Fam (1476–1918 aa) was ex-
pressed as a MBP fusion protein, and was purified with amylose resin
(New England Biolabs, Inc., Beverly, MA). MBP-Fam (1476–1918 aa;
0.05, 0.125, 0.25, 1.25, 2.5, and 7.5 nmol) was mixed with glutathione-
Sepharose 4B beads (30 ml) coated with 0.3 nmol of either GST or GST-
AF-6 (1130–1612 aa) in 250 ml of buffer B. The beads were washed six
times with 100 ml of buffer B, and were then washed three times with 100 ml
of buffer B containing 50 mM NaCl. The bound MBP-Fam (1476–1918 aa)
was coeluted with GST or GST-AF-6 (1130–1612 aa) by adding 100 ml of
buffer B containing 10 mM glutathione three times. Portions (30 ml each)
of the three fractions of the glutathione-eluates were subjected to SDS-
PAGE, followed by Coomassie Brilliant Blue staining. MBP-Fam (1476–
1918 aa) was visualized and estimated with a densitograph (ATTO, To-
kyo, Japan).
Effect of Proteasome Inhibitor on Rat1 and EL Cells
Rat1 and EL cells were seeded in 100-mm tissue culture dishes at a cell
density of 1 3 106 cells/dish, and were cultured for 24 h. The cells were
then treated with 25 mM ALLN or ALLM for 3 h. ALLN and ALLM
were dissolved in DMSO to a final concentration of 10 mM. The cells
were washed twice with PBS and lysed in 360 ml of buffer D (50 mM Tris/
HCl at pH 7.5, 100 mM KCl, 4 mM EGTA, 1 mM NaF, 1 mM sodium van-
adate, 0.25% Triton X-100, 10 mM p-APMSF, 1 mg/ml leupeptin, 25 mM
ALLN, and 300 mM sucrose). The cell lysates of Rat1 and EL cells were
subjected to SDS-PAGE and immunoblotted with anti-AF-6 (#4) anti-
body, polyclonal antibody against b-catenin, or anti-a-catenin antibody.
Ubiquitination Assay of AF-6 In Vivo
COS7 cells were seeded on 60-mm tissue culture dishes at a cell density of
6 3 105 cells/dish, and were cultured for 16 h. COS7 cells were transfectedThe Journal of Cell Biology, Volume 142, 1998 1056
with pEF-BOS-AF-6-myc (12 mg) and pMT123 (HA-ubiquitin; 3 mg) by
the standard DEAE-dextran method (Lopata et al., 1984). To examine
the effect of the proteasome inhibitor ALLN, COS7 cells were grown for
30 h after transfection, and were then treated with 25 mM ALLN for 18 h.
The cells were washed twice with PBS and lysed in 360 ml of buffer D. An
immunoprecipitation analysis with anti-AF-6 antibody (#3) was per-
formed as described above. The samples were subjected to SDS-PAGE
followed by immunoblot analysis using anti-HA antibody.
Deubiquitination Assay of the Ubiquitinated AF-6
by Fam
The plasmids pEF-BOS-AF-6-myc (12 mg) and pMT123 (3 mg) were
transfected with or without pEF-BOS-HA-Fam-CAT (5 mg) in COS7
cells. Immunoprecipitation and an immunoblot analysis were carried out
as described above.
Other Procedures
SDS-PAGE was performed as described (Laemmli, 1970). Protein con-
centrations were determined with BSA as the reference protein as de-
scribed (Bradford, 1976). Immunoblot analyses were carried out as de-
scribed (Harlow and Lame, 1988).
Results
Identification of AF-6
(1130–1612 aa)-interacting Molecules
To detect molecules interacting with AF-6 (1130–1612 aa),
which includes a proline-rich region, the bovine brain cy-
tosolic fraction was loaded onto affinity columns coated
with GST, GST-AF-6 (1130–1612 aa), or GST-CD44. The
proteins bound to the affinity columns were coeluted with
GST-AF-6 (1130–1612 aa) by adding glutathione. The glu-
tathione-eluted fractions were subjected to SDS-PAGE
followed by silver staining. A protein with a molecular
mass of z220 kD (p220) was detected in the glutathione
eluate from the GST-AF-6 (1130–1612 aa) affinity column,
but not from the GST or GST-CD44 affinity columns (Fig.
1 a), indicating that p220 specifically interacts with AF-6
(1130–1612 aa) directly or indirectly. To identify the AF-6
(1130–1612 aa)-interacting molecule, p220 was subjected
to amino acid sequencing as described in Materials and
Methods. Two peptide sequences derived from p220 were
determined. These were LSVPATFMLVSLD and NDY-
FEF. Both peptide sequences were identical to the de-
duced amino acid sequence of mouse Fam, which is one of
the deubiquitinating enzymes (Wood et al., 1997).
Fam shows homology with Ubps-type deubiquitinating
enzyme in Drosophila, the product of the fat facets (faf)
gene. Recent genetic analyses indicate that the faf gene is
required for normal eye development and embryogenesis,
suggesting that the deubiquitinating activity of the faf
product plays a critical role in controlling the cell fate. The
amino acid sequence of Fam shows z50% amino acid
identity and 70% similarity with that of Faf (Wood et al.,
1997). Fam has the cysteine and histidine domains charac-
teristic of Ubps. Fam shows a high similarity to several
Ubps from yeast to mammals in these two regions (Wood
et al., 1997). The calculated molecular mass of mouse Fam
is 290 kD, but the apparent molecular mass of bovine Fam
estimated by SDS-PAGE is z220 kD. To confirm that
p220 is Fam, an immunoblot analysis was performed on
p220 from the glutathione-eluted fraction with two anti-
Fam antibodies. Anti-Fam antibody (N20) against 20 aa of
the amino-terminal site and anti-Fam antibody (C114)
against 114 aa of the carboxy-terminal site were generated.
Since p220 was recognized by both anti-Fam antibodies
(N20 and C114) as shown in Fig. 1 b, we judged that p220 was
the full length of Fam, but not the degradation product of
Fam. We therefore concluded that p220 was the bovine coun-
terpart of mouse Fam, and hereafter refer to it as Fam.
Deubiquitinating Activity Catalyzed by Fam
First we examined whether Fam has deubiquitinating ac-
tivity. We used the 200-mM NaCl eluate from the GST-
AF-6 (1130–1612 aa) affinity column as a source of Fam.
Fam was incubated with the 125I-labeled ubiquitin-conju-
gated PEST sequence (Ub-PEST) for various periods of
time. As shown in Fig. 2, Fam could release ubiquitin from
Ub-PEST (a), and could produce the hydrolyzed 125I-
PEST peptides from Ub-PEST (b). In the Fam minus con-
trol of Fig. 2, the 200-mM NaCl buffer that did not contain
any enzyme was used. These results indicate that Fam is
able to generate free ubiquitin from Ub-PEST. It is well-
known that ubiquitin-aldehyde (Ub-CHO) inhibits Ubps.
Release of ubiquitin from Ub-PEST or production of the
PEST peptides was almost abolished in the presence of
Ub-CHO. The deubiquitinating activity was not detected
in the 200-mM NaCl eluate from the GST affinity column
Figure 1. Purification of AF-6-interacting protein. (a) The bovine
brain cytosol was loaded onto glutathione-Sepharose 4B columns
coated with GST, GST-AF-6 (1130–1612 aa), or GST-CD44. The
bound proteins were coeluted with the respective GST fusion
proteins by adding glutathione. Aliquots of the eluates were re-
solved by SDS-PAGE, followed by silver staining. Lane 1, GST;
lane 2, GST-AF-6 (1130–1612 aa); lane 3, GST-CD44. The arrow-
head denotes the position of p220. (b) Protein p220 was immuno-
blotted with the anti-Fam antibodies. Lane 1, the position of p220
by silver staining; lane 2, with preimmuneserum; lane 3, with the
anti-Fam antibody (N20); lane 4, with the anti-Fam antibody
(C114). The arrowhead denotes the position of p220. The results
shown are representative of three independent experiments.Taya et al. AF-6 and Fam Deubiquitinating Enzyme 1057
(data not shown). These results demonstrated that Fam
has deubiquitinating activity.
Distributions of Fam in Confluent MDCKII Cells
To understand the functions of Fam, we examined its in-
tracellular distribution in MDCKII epithelial cells that
show characteristics of polarized epithelial cells and form
the junctional complex, including the tight junction and
adherens junction at cell–cell contact sites (Gonzalez-
Mariscal et al., 1985). The immunoblot analysis of cell ly-
sates from MDCKII cells showed that anti-Fam antibody
recognized a single band corresponding to a molecular
weight of z220 kD (Fig. 3 A) as in the case of bovine brain
extract (Fig. 1 b). Antibody preincubation with the recom-
binant Fam abolished the immunoreactivity (data not
shown). The immunoreactivity of Fam was specifically lo-
calized at sites where a cell contacted a neighboring cell,
and not at free ends of plasma membranes (Fig. 3 B). The
cytoplasm exhibited a relatively low level of immunoreac-
tivity. To further examine whether Fam exists in the apical
or basal site of the lateral membrane, cellular distribution
of Fam was compared with that of ZO-1 and b-catenin
(Fig. 3, C, b and e). ZO-1 was concentrated at the apical
sections, whereas b-catenin was found at more basal sec-
tions as described previously (Nagafuchi and Takeichi,
1989; Itoh et al., 1993). In contrast, Fam immunoreactivity
was colocalized at the immunofluorescence microscopic
level with ZO-1 at the apical sites, and with b-catenin at
the basal sites (Fig. 3, C, c and f). Since we have previously
shown that AF-6 interacts with ZO-1 and is colocalized
with ZO-1 at cell–cell contact sites including tight junc-
tions (Yamamoto et al., 1997), part of the Fam that is lo-
calized at the same sites with ZO-1 may be colocalized
with AF-6. We also found that accumulation of Fam is in-
duced by the formation of cell–cell adhesions by using a
Ca21 switch assay in MDCKII cells (data not shown).
These results suggest that Fam is partly colocalized with
AF-6 at apical sites of the lateral membrane in confluent
MDCKII cells.
Interaction of Fam and AF-6 In Vivo
Because Fam was partly colocalized with AF-6 at apical
sites of the lateral membrane, we examined whether Fam
interacts with AF-6 in vivo. When Fam was immunopre-
cipitated with anti-Fam antibody from confluent MDCKII
cells, AF-6 was coimmunoprecipitated with Fam (Fig. 4 a).
AF-6 was not coimmunoprecipitated with control preim-
muneserum. AF-6 appeared to associate with Fam with a
stoichiometry of about one AF-6 per ten Fam under these
conditions. Similarly, Fam was also coimmunoprecipitated
with AF-6 (Fig. 4 b) when AF-6 was immunoprecipitated
with anti-AF-6 antibody from confluent MDCKII cells.
Figure 2. Hydrolysis of 125I-labeled Ub-PEST by Fam. The 125I-
labeled Ub-PEST was incubated alone or with 1.6 mg of Fam pu-
rified by GST-AF-6 (1130–1612 aa) affinity column in the ab-
sence or presence of ubiquitin-aldehyde (Ub-CHO) for 1, 3, or
6 h at 378C. After the incubation, the samples were subjected to
SDS-PAGE, followed by Coomassie Brilliant Blue staining (a),
and by autoradiography (b). The release of ubiquitin from Ub-
PEST (a) or the production of the hydrolysis of 125I-labeled PEST
peptides from Ub-PEST (b). The results shown are representa-
tive of three independent experiments.
Figure 3. Confocal microscope images of confluent MDCKII
cells showing the distributions of Fam, ZO-1 and b-catenin. (A)
Immunoblot analysis of MDCKII cell lysates with preimmune se-
rum (lane 1) and with anti-Fam antibody (K2; lane 2). The arrow-
head denotes the position of Fam. (B) Subconfluent MDCKII
cells stained with anti-Fam antibody (K2). Arrows indicate free
ends of plasma membrane. (C) Confluent MDCKII cells doubly
stained with a rabbit polyclonal antibody against Fam (K2; a and
d) and mouse monoclonal antibodies against ZO-1 (b) or b-cate-
nin (e). Fam immunoreactivity is shown in green, and ZO-1 and
b-catenin immunoreactivities are shown in red. ZO-1 was con-
centrated at the apical sections (b), whereas b-catenin was found
at more basal sections (e). The yellow area indicates colocaliza-
tion of Fam and ZO-1 at the apical sites (c), or Fam and b-catenin
at the basal sites (f). The results shown are representative of
three independent experiments. Bar, 10 mm.The Journal of Cell Biology, Volume 142, 1998 1058
These results indicate that Fam interacts with AF-6 in
vivo.
Interaction of Fam and AF-6 In Vitro
We examined which domain of Fam interacts with AF-6
using in vitro–translated Fam such as Fam (1–669 aa), Fam
(670–1213 aa), Fam (1210–2100 aa), and Fam (2097–2554
aa; Fig. 5 a). Affinity beads coated with GST or GST-AF-6
(1130–1612 aa) were mixed with the in vitro–translated
Fam (1–669 aa), Fam (670–1213 aa), Fam (1210–2100 aa),
and Fam (2097–2554 aa), and the interacting proteins were
then coeluted with GST fusion proteins by adding glu-
tathione. As shown in Fig. 5 b, Fam (1210–2100 aa) bound
to GST-AF-6 (1130–1612 aa), but Fam (1–669 aa), Fam
(670–1213 aa), and Fam (2097–2554 aa) did not. Fam
(1210–2100 aa) did not bind to control GST.
To test the specificity of the binding, we carried out a ki-
netic study of the binding of Fam to AF-6. We first exam-
ined whether GST-AF-6 (1130–1612 aa) could bind to
MBP-Fam (1476–1918 aa) involving the deubiquitinating
catalytic domain. Affinity beads coated with GST or GST-
AF-6 (1130–1612 aa) were mixed with MBP-Fam (1476–
1918 aa). The bound MBP-Fam (1476–1918 aa) was then
coeluted with the GST fusion proteins by adding glu-
tathione, and the eluted MBP-Fam (1476–1918 aa) was de-
tected by Coomassie Brilliant Blue staining. MBP-Fam
(1476–1918 aa) was detected in the eluates from the GST-
AF-6 (1130–1612 aa) affinity beads, but only slightly in
those from the GST affinity beads (data not shown). In ad-
dition, as shown in Fig. 6, MBP-Fam (1476–1918 aa)
bound to GST-AF-6 (1130–1612 aa) in a dose-dependent
manner, and this binding was saturable when the amounts
of MBP-Fam (1476–1918 aa) were increased (Fig. 6, a and
b). The apparent Kd value for binding MBP-Fam (1476–
1918 aa) to GST-AF-6 (1130–1612 aa) was estimated to be
z810 nM under the conditions used. These results indicate
that mainly 1476–1918 aa of Fam is responsible for binding
Fam to AF-6.
Ubiquitination of AF-6 In Vivo
As described above, AF-6 interacts with Fam, and the AF-
6–interacting domain of Fam involves the deubiquitinating
catalytic domain of Fam. This raises the possibility that
AF-6 is the substrate of Fam, and that AF-6 is Ub-conju-
gated and subjected to the ubiquitin–proteasome pathway.
First, to determine whether AF-6 is degraded by the pro-
teasome-dependent proteolysis pathway, Rat1 fibroblasts
and EL cells were treated with the proteasome inhibitor.
Figure 4. Coimmunoprecipitation of Fam with AF-6. MDCKII
cells were lysed and solubilized with buffer C (see Materials and
Methods). This sample was incubated with preimmuneserum
(lane  1), with anti-Fam antibody (K2; lane 2), or with anti-AF-6
antibody (#3; lane 3). The immunocomplexes were then precipi-
tated with protein A-Sepharose 4B, and subjected to immunoblot
analysis using anti-AF-6 antibody (#4; a) or anti-Fam antibody
(N20; b). The arrowheads denote the positions of AF-6 (a) and
Fam (b), respectively. The results shown are representative of
three independent experiments.
Figure 5. Interaction of in vitro–translated Fam (1210–2100 aa)
with GST-AF-6 (1130–1612 aa). (a) Domain diagram of Fam and
the recombinant fragments used for the in vitro binding assay.
D.U., catalytic site of deubiquitinating enzyme including cysteine
and histidine domains. Bold lines show the recombinant frag-
ments used for the in vitro binding assay. (b) In vitro–translated
Fam (1–669 aa; lanes 1 and 2), Fam (670–1213 aa; lanes 3 and 4),
Fam (1210–2100 aa; lanes 5 and 6), and Fam (2097–2554 aa; lanes
7 and 8) were mixed with GST (lanes 1, 3, 5, and 7) or GST-AF-6
(1130–1612 aa; lanes 2, 4, 6, and 8)-coated glutathione-Sepharose
4B beads. The interacting proteins were coeluted with GST fu-
sion proteins by adding glutathione. The eluates were subjected
to SDS-PAGE and vacuum-dried. The in vitro–translated Fam
fragments were visualized with an image analyzer. The arrow-
head denotes the position of the in vitro-translated Fam (1210–
2100 aa). The results shown are representative of three indepen-
dent experiments.Taya et al. AF-6 and Fam Deubiquitinating Enzyme 1059
EL cells are L cells stably expressing E-cadherin (Nagafu-
chi et al., 1994). It is well-known that the peptide aldehyde
ALLN inhibits the proteasome-dependent proteolysis
pathway, leading to an accumulation of proteins that are
usually metabolized by the proteasome pathway (Coux
et al., 1996). ALLM is the related peptide aldehyde and a
calpain inhibitor, but it does not inhibit the proteasome
pathway. Recently some groups reported that the turnover
of  b-catenin is regulated by the ubiquitin–proteasome
pathway (Aberle et al., 1997; Orford et al., 1997). They
showed that treating certain cell lines with ALLN resulted
in accumulation of the higher molecular weight b-catenin.
It has been reported that such a modification in a-catenin
was not observed when cells were treated with ALLN. We
obtained similar results as shown in Fig. 7, b and c, when
Rat1 and EL cells were treated with ALLN. To determine
whether AF-6 shows the similar modification, we immuno-
blotted the cell lysates with anti-AF-6 antibody. The
higher molecular weight forms of AF-6 were detected by
the treatment with ALLN, but little was detected by the
treatment with ALLM under the same conditions (Fig. 7
a). These results suggest that AF-6 is degraded by the pro-
teasome pathway.
Next, to determine whether AF-6 is ubiquitinated, we
performed an assay to detect ubiquitinated proteins
(Treier  et al., 1994; Aberle et al., 1997). AF-6 and hemag-
glutinin-tagged ubiquitin (HA-Ub) were transiently ex-
pressed in COS7 cells. The immunoprecipitates were then
collected with anti-AF-6 antibody and subjected to an im-
munoblot analysis with anti-HA antibody. As shown in
Fig. 8, HA-Ub–conjugated AF-6 was detected in cells ex-
pressing HA-Ub, but not in control cells. We examined
the effect of ALLN on AF-6 ubiquitination. HA-Ub–con-
jugated proteins were more strongly detected in the cells
treated with ALLN than in the untreated cells (Fig. 8).
The band below HA-Ub–conjugated AF-6 was as strong
as HA-Ub–conjugated AF-6 in the lane of ALLN plus.
The lower band was probably the degradation product of
the full-length AF-6, because the lower band as well as the
upper band were detected only when the AF-6 cDNA was
transfected. It may be noted that the intensity of the lower
band was more strongly enhanced by ALLN, though we
can not give the precise reasons for this phenomenon.
Taken together, these results indicate that AF-6 is ubiqui-
tinated in vivo and suggest that the ubiquitinated AF-6 is
degraded by the proteasome pathway.
Deubiquitination of the Ubiquitinated AF-6
by Fam-CAT
For the determination of whether Fam can release ubiq-
uitin from the ubiquitinated AF-6 in vivo, AF-6 and HA-
Ub were expressed with or without Fam-CAT in COS7
Figure 6. Interaction of MBP-Fam (1476–1918 aa) and GST-AF-6
(1130–1612 aa) in vitro. The result of the kinetic study of the
binding of MBP-Fam (1476–1918 aa) with GST-AF-6 (1130–1612
aa) are shown. Various amounts of MBP-Fam (1476–1918 aa)
were mixed with GST (lanes 1, 3, 5, 7, 9, and 11) or GST-AF-6
(1130–1612 aa) (lanes 2, 4, 6, 8, 10, and 12)-coated glutathione-
Sepharose 4B beads. The interacting proteins were coeluted with
GST fusion proteins by adding glutathione. (a) The eluted MBP-
Fam (1476–1918 aa) was detected by Coomassie Brilliant Blue
staining. (b) The bound MBP-Fam (1476–1918 aa) was visualized
and estimated with a densitograph. The values shown are means 6
SEM of triplicate experiments.
Figure 7. Regulation of AF-6 by the ubiquitin–proteasome path-
way. Rat1 and EL cells were treated with the vehicle (DMSO;
lanes 1 and 4), 25 mM ALLM (lanes 2 and 5), or 25 mM ALLN
(lanes 3 and 6) for 3 h. Cell lysates of Rat1 (lanes 1–3) and EL
(lanes 4–6) cells were immunoblotted with anti-AF-6 antibody
(#4; a), anti-b-catenin antibody (b), and anti-a-catenin antibody
(c). The arrowheads denote the position of the ubiquitinated AF-6
(a) and the ubiquitinated b-catenin (b), respectively. The results
shown are representative of three independent experiments.The Journal of Cell Biology, Volume 142, 1998 1060
cells. We used Fam-CAT, which includes the deubiquiti-
nating catalytic domain of Fam (1210–2410 aa), because
we could not detect the expression of full-length Fam,
probably due to its low expression level. As described
above, AF-6 was immunoprecipitated from the cell lysates
with anti-AF-6 antibody, and the immunoprecipitates
were subjected to an immunoblot analysis with anti-HA
antibody. In the absence of Fam-CAT, HA-Ub–conju-
gated AF-6 was observed (Fig. 9) as shown in Fig. 8. When
AF-6 was coexpressed with Fam-CAT, the amount of HA-
Ub–conjugated AF-6 was reduced while the amount of im-
munoprecipitated AF-6 was not affected (Fig. 9). These
results indicate that Fam inhibited the ubiquitination of
AF-6, and suggest that AF-6 is one of the substrates of Fam.
Discussion
Interaction of AF-6 and Fam
We here identified Fam as an AF-6 (1130–1612 aa)–inter-
acting protein. The carboxyl terminal domain of AF-6
(1130–1612 aa) has the proline-rich region. Since it has
been reported that the proline-rich region interacts with
certain proteins containing the src homology region 3
(SH3) or WW domain (Sudol, 1996), we first thought that
AF-6 (1130–1612 aa) may interact with proteins contain-
ing the SH3 or WW domain. The present results, however,
showed that the AF-6 (1130–1612 aa) containing the pro-
line-rich region interacts with Fam, which has neither an
SH3 nor a WW domain, and that the AF-6–interacting do-
main of Fam involves the cysteine and histidine domains
characteristic of Ubps.
As described above, Fam is partly colocalized with AF-6
at cell–cell contact sites, but not at free ends of the plasma
membrane. We also found that accumulation of Fam is in-
duced by formation of cell–cell adhesions by using a Ca21
switch assay in MDCKII cells (data not shown). These ob-
servations raised the possibility that AF-6 may function as
an anchoring molecule for recruiting Fam to cell–cell con-
tact sites. Fam is, however, widely distributed at other lat-
eral membranes where AF-6 is not localized. In this case,
Fam may be recruited to lateral membranes by interacting
with other cell–cell adhesion molecules. In this regard, we
have recently found that Fam interacts with b-catenin, but
not with a-catenin and the cytoplasmic domain of E-cad-
herin in vitro (unpublished results). Investigations to iden-
tify the Fam-interacting molecules are in progress; their
findings may clarify the mechanisms by which Fam is re-
cruited to cell–cell contact sites.
Ubiquitination of AF-6
Since the AF-6–interacting domain of Fam involves the
deubiquitinating catalytic domain of Fam, we speculate
that AF-6 is the substrate of Fam, and is subjected to the
ubiquitin–proteasome pathway. As described above, when
Rat1 and EL cells were treated with the proteasome inhib-
itor ALLN, the higher molecular weight forms of AF-6
were detected. We also performed an assay for detecting
the ubiquitinated proteins (Treier et al., 1994; Aberle et al.,
1997) and found that AF-6 was ubiquitinated in vivo.
Many proteins involved in cell cycle control, transcription
activation, cell growth, antigen presentation, and so on are
known to be regulated by the ubiquitin–proteasome path-
way. These proteins include c-fos, NFkB-IkB complex,
p53 and growth factor receptors such as PDGFR and
FGFR-1, and it has been gradually clarified how these pro-
teins are subjected to the ubiquitin–proteasome pathway
(Hochstrasser, 1995; Hicke, 1997). It remains to be clari-
fied how AF-6 is ubiquitinated and subsequently degraded
by the proteasome pathway.
Deubiquitination of AF-6 by Fam
Fam belongs to the deubiquitinating enzyme, and we
showed that Fam has deubiquitinating activity in vitro
(Fig. 2). Indeed, we found that Fam-CAT decreases the
amount of HA-Ub–conjugated AF-6 in COS7 cells (Fig.
Figure 8. Ubiquitination of AF-6 in COS7 cells. AF-6 and HA-
tagged ubiquitin (HA-Ub) were expressed in COS7 cells. COS7
cells were treated with or without 25 mM ALLN for 18 h. The im-
munoprecipitates were then collected with anti-AF-6 antibody
(#3) and subjected to an immunoblot analysis with anti-HA anti-
body. The arrowhead denotes the position of HA-Ub-conjugated
AF-6. The results shown are representative of three independent
experiments.
Figure 9. Deubiquitination of the ubiquitinated AF-6 by Fam-
CAT. AF-6 and HA-tagged ubiquitin (HA-Ub) were expressed
with or without Fam-CAT (the deubiquitinating catalytic domain
of Fam) in COS7 cells. The immunoprecipitates were then col-
lected with anti-AF-6 antibody (#3), and subjected to an immu-
noblot analysis with anti-HA antibody or anti-AF-6 antibody
(#4). The arrowhead denotes the position of HA-Ub–conjugated
AF-6, and the arrow denotes the position of the immunoprecipi-
tated AF-6. The results shown are representative of three inde-
pendent experiments.Taya et al. AF-6 and Fam Deubiquitinating Enzyme 1061
9), suggesting that Fam can release ubiquitin from AF-6,
although we cannot exclude the possibility that Fam sim-
ply inhibits the ubiquitination of AF-6. Whether Fam-
CAT is expressed or not in Fig. 9, the AF-6 level was simi-
lar. We first thought that the AF-6 level might increase
when Fam-CAT was expressed. However, HA-Ub–conju-
gated AF-6 was only z5% of the total AF-6 under our
conditions. Thus, we think that we can not detect a big
change of the AF-6 level in this assay.
Since Fam is widely distributed at lateral membranes, it
is possible that Fam deubiquitinates components of cell–
cell adhesions including b-catenin. We have recently found
that Fam interacts with b-catenin in vitro as described
above. However, we could not examine whether b-catenin
is the substrate of Fam because exogenous b-catenin was
hardly ubiquitinated in COS7 cells under our assay condi-
tions. Further studies are necessary to resolve this problem
and to clarify the substrate spectrum of the Fam deubiq-
uitinating enzyme.
Possible Roles of Fam at Cell–Cell Adhesions
Polarized epithelial cells form the junctional complex, in-
cluding tight junctions and adherens junctions, at cell–cell
contact sites (Gonzalez-Mariscal et al., 1985). In epithelial
and endothelial cells, ZO-1 is directly associated with oc-
cludin, which has four transmembrane domains in its
amino-terminal half, in tight junctions (Itoh et al., 1993;
Furuse et al., 1993). In nonepithelial cells, ZO-1 is concen-
trated at adherens junctions, and is associated with a cad-
herin/catenin complex via a direct interaction with a-cate-
nin (Itoh et al., 1993; Itoh et al. 1997). Since AF-6 directly
interacts with ZO-1 and Fam, we propose that the roles of
Fam in epithelial cells and nonepithelial cells are as fol-
lows: Fam is probably recruited to tight junctions or adhe-
rens junctions via direct interaction with AF-6. When cells
move and enter the mitotic phase, cell–cell adhesions ap-
pear to be perturbed or dynamically rearranged. These
perturbations or rearrangements of cell–cell adhesions
may be regulated by the ubiquitin-proteasome pathway.
Fam probably maintains the stability of cell–cell adhesions
by deubiquitinating the components of cell–cell adhesions.
It remains to be determined whether Fam deubiquitinates
the components of cell–cell adhesions.
The transformation of epithelial and fibroblastic cells by
activated Ras results in the perturbation of cell–cell adhe-
sions. We observed that the formation of the AF-6/ZO-1
complex is specifically inhibited or changed by activated
Ras, as described previously (Yamamoto et al., 1997).
Since this alteration by activated Ras may prevent recruit-
ment of Fam to the cell–cell adhesions or inhibit the de-
ubiquitinating activity of Fam, Fam may become unable to
contribute to the stability of cell–cell adhesions. It remains
to be clarified whether the function of Fam is regulated by
Ras signaling and is implicated in the Ras-induced trans-
formation.
The Interaction of AF-6-Fam Pathway with
Ras Signaling
AF-6 shows strong sequence homology with Drosophila
Canoe, and shares a common domain organization with
Canoe (Kuriyama et al., 1996). The Drosophila compound
eye consists of 800 identical facets that are each made up
of eight photoreceptors (R1–R8) and four cone cells. Ca-
noe is implicated in cone cell formation in the developing
compound eye in Drosophila (Matsuo et al., 1997). The
fates of cone cells are thought to be determined by cell–
cell contacts. The phenotypic effect of Canoe mutations on
the cone cells depends on the state of Ras (Matsuo et al.,
1997), and Canoe is shown to interact with the activated
Ras, indicating that Canoe serves as a target of Ras, as de-
scribed for AF-6 (Kuriyama et al., 1996; Matsuo et al.,
1997).
Here we showed that AF-6 interacts with Fam in vitro
and in vivo. Fam is homologous to a deubiquitinating en-
zyme in Drosophila, the product of the fat facets (faf) gene
(Huang et al., 1995; Wood et al., 1997). Faf is essential for
regulating of a cell communication pathway in the early
stage of eye development. Faf regulates the number of
photoreceptor cells in each facet of the compound eye
(Fischer-Vize et al., 1992; Huang and Fischer-Vize, 1996).
When the deubiquitinating activity of Faf is abolished by
mutagenesis in Drosophila, the mutant fly has an abnor-
mal eye morphology, suggesting that the deubiquitinating
activity of Faf is necessary for the normal eye develop-
ment (Huang et al., 1995). It was recently reported that
Ras1 interacts genetically with Faf in Drosophila eye de-
velopment (Li et al., 1997). Faf has an additional function
in the later stage of eye development involving Ras1.
These observations in Drosophila raise the possibility that
both Faf and Canoe function downstream of Ras and that
Faf interacts genetically with Canoe, although further ge-
netic analyses are required to determine the relation of the
Ras1-Canoe and Ras1-Faf pathways.
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